Cargando…

Immune-Mediated Therapies for Liver Cancer

In recent years, immunotherapy has gained renewed interest as an alternative therapeutic approach for solid tumors. Its premise is based on harnessing the power of the host immune system to destroy tumor cells. Development of immune-mediated therapies, such as vaccines, adoptive transfer of autologo...

Descripción completa

Detalles Bibliográficos
Autores principales: Aravalli, Rajagopal N., Steer, Clifford J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333065/
https://www.ncbi.nlm.nih.gov/pubmed/28218682
http://dx.doi.org/10.3390/genes8020076
_version_ 1782511654165020672
author Aravalli, Rajagopal N.
Steer, Clifford J.
author_facet Aravalli, Rajagopal N.
Steer, Clifford J.
author_sort Aravalli, Rajagopal N.
collection PubMed
description In recent years, immunotherapy has gained renewed interest as an alternative therapeutic approach for solid tumors. Its premise is based on harnessing the power of the host immune system to destroy tumor cells. Development of immune-mediated therapies, such as vaccines, adoptive transfer of autologous immune cells, and stimulation of host immunity by targeting tumor-evasive mechanisms have advanced cancer immunotherapy. In addition, studies on innate immunity and mechanisms of immune evasion have enhanced our understanding on the immunology of liver cancer. Preclinical and clinical studies with immune-mediated therapies have shown potential benefits in patients with liver cancer. In this review, we summarize current knowledge and recent developments in tumor immunology by focusing on two main primary liver cancers: hepatocellular carcinoma and cholangiocarcinoma.
format Online
Article
Text
id pubmed-5333065
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-53330652017-03-13 Immune-Mediated Therapies for Liver Cancer Aravalli, Rajagopal N. Steer, Clifford J. Genes (Basel) Review In recent years, immunotherapy has gained renewed interest as an alternative therapeutic approach for solid tumors. Its premise is based on harnessing the power of the host immune system to destroy tumor cells. Development of immune-mediated therapies, such as vaccines, adoptive transfer of autologous immune cells, and stimulation of host immunity by targeting tumor-evasive mechanisms have advanced cancer immunotherapy. In addition, studies on innate immunity and mechanisms of immune evasion have enhanced our understanding on the immunology of liver cancer. Preclinical and clinical studies with immune-mediated therapies have shown potential benefits in patients with liver cancer. In this review, we summarize current knowledge and recent developments in tumor immunology by focusing on two main primary liver cancers: hepatocellular carcinoma and cholangiocarcinoma. MDPI 2017-02-17 /pmc/articles/PMC5333065/ /pubmed/28218682 http://dx.doi.org/10.3390/genes8020076 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Aravalli, Rajagopal N.
Steer, Clifford J.
Immune-Mediated Therapies for Liver Cancer
title Immune-Mediated Therapies for Liver Cancer
title_full Immune-Mediated Therapies for Liver Cancer
title_fullStr Immune-Mediated Therapies for Liver Cancer
title_full_unstemmed Immune-Mediated Therapies for Liver Cancer
title_short Immune-Mediated Therapies for Liver Cancer
title_sort immune-mediated therapies for liver cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333065/
https://www.ncbi.nlm.nih.gov/pubmed/28218682
http://dx.doi.org/10.3390/genes8020076
work_keys_str_mv AT aravallirajagopaln immunemediatedtherapiesforlivercancer
AT steercliffordj immunemediatedtherapiesforlivercancer